As antibodies are known to play a role in tumor immunosurveillance and MDSC are known to suppress most immune effector mechanisms including B cells, we asked if increases in MDSC we described above could have influenced the ability of individuals with premalignancies to mount anti-MUC1 antibody responses. This evidence concerns the gene MUC1 and neoplasm.